BioSpace News Archive

ValGenesis Inc., a market leader in enterprise Validation Lifecycle Management Systems (VLMS), and Zenovative, a technology development and consulting company based in Maryland, USA, have partnered to deliver unique compliance-focused digital validation solutions for pharmaceutical companies across the globe.

Alercell, announced today that it will begin distributing a Leukemia Fusion Gene Screening and Genotyping Kit created and manufactured by Zeesan, a longtime partner of Alercell.

Vectorious Medical Technologies Ltd., today announced that it has enrolled the first six patients in the VECTOR-HF II Study, which will evaluate the V-LAP System’s novel approach of patient self-management for detecting and managing heart failure (HF) early, before it further damages the heart.

Janux Therapeutics today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obstetricians and Gynecologists (ACOG) annual meeting.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data.

Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious Gold 2022 Edison Award for its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options.

Market leading innovator in laboratory digital transformation, Scitara, has announced a collaboration with scientific analytical technology leader, PerkinElmer.

Rising incidence of trauma, stroke, and heart attack is expected to increase demand for air medical services, which is one of the key factors driving market revenue growth.

Pharming Group N.V. announces that it has received a positive decision from the UK’s Medicines and Healthcare Products Regulatory Agency on a Paediatric Investigation Plan submission for leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, for the treatment of activated phosphoinositide 3-kinase delta syndrome in patients from 1 year of age to less than 18 years of age.